Enanta Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Operating Revenue	66.98	65.32	67.64	79.2	86.16	97.07
Revenue	66.98	65.32	67.64	79.2	86.16	97.07
Revenue Growth (YoY)	0.58%	-3.42%	-14.61%	-8.07%	-11.24%	-20.74%
Gross Profit	66.98	65.32	67.64	79.2	86.16	97.07
Selling, General & Admin	40.1	43.93	57.85	52.89	45.48	32.54
Research & Development	99.94	106.74	131.48	163.52	164.52	174.11
Operating Expenses	140.04	150.67	189.33	216.41	210	206.65
Operating Income	-73.06	-85.35	-121.69	-137.21	-123.84	-109.57
Interest Expense	-8.8	-7.68	-10.94	-5.15	-	-
Interest & Investment Income	8.96	9.95	13.63	8.5	2.74	2.02
Other Non Operating Income (Expenses)	0.04	0.04	0.07	-	0.08	-0.03
EBT Excluding Unusual Items	-72.87	-83.05	-118.93	-133.85	-121.02	-107.58
Gain (Loss) on Sale of Investments	0.11	-0.5	1.14	2.86	-1.17	-
Pretax Income	-72.76	-83.55	-117.79	-131	-122.19	-107.58
Income Tax Expense	-1.22	-1.66	-1.74	2.82	-0.43	-28.58
Net Income	-71.54	-81.89	-116.05	-133.82	-121.76	-79
Net Income to Common	-71.54	-81.89	-116.05	-133.82	-121.76	-79
Shares Outstanding (Basic)	23	21	21	21	21	20
Shares Outstanding (Diluted)	23	21	21	21	21	20
Shares Change (YoY)	9.53%	0.85%	0.90%	1.78%	2.14%	1.16%
EPS (Basic)	-3.08	-3.84	-5.48	-6.38	-5.91	-3.92
EPS (Diluted)	-3.08	-3.84	-5.48	-6.38	-5.91	-3.92
Free Cash Flow	-18.46	-32.17	-96.71	-112.21	-86.91	-70.75
Free Cash Flow Per Share	-0.80	-1.51	-4.57	-5.35	-4.22	-3.51
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-109.08%	-130.66%	-179.92%	-173.23%	-143.74%	-112.88%
Profit Margin	-106.80%	-125.36%	-171.58%	-168.95%	-141.31%	-81.38%
Free Cash Flow Margin	-27.57%	-49.24%	-142.99%	-141.67%	-100.87%	-72.88%
EBITDA	-68.13	-80.76	-119.36	-134.84	-120.87	-106.24
EBITDA Margin	-101.72%	-123.63%	-176.47%	-170.24%	-140.29%	-109.44%
D&A For EBITDA	4.93	4.59	2.34	2.37	2.97	3.33
EBIT	-73.06	-85.35	-121.69	-137.21	-123.84	-109.57
EBIT Margin	-109.08%	-130.66%	-179.92%	-173.23%	-143.74%	-112.88%
Revenue as Reported	66.98	65.32	67.64	79.2	86.16	97.07

Source: S&P Global Market Intelligence. Standard template. Financial Sources.